Berberine, the active compound in RKI-609, has been used in traditional Chinese medicine for over 2,000 years. The Berberis plant, from which berberine is extracted, was first recorded in the Shennong Ben Cao Jing, a classic Chinese medical text, as a treatment for various health conditions, including diarrhea, dysentery, and conjunctivitis. In the 20th century, scientists began to isolate and study berberine, leading to a deeper understanding of its pharmacological properties and therapeutic potential.
| Feature | Ibrutinib (1st Gen) | Pirtobrutinib (3rd Gen) | | | :--- | :--- | :--- | :--- | | Binding Type | Covalent (C481) | Non-covalent | Non-covalent (Type II) | | C481S Active | No | Yes | Yes | | Selectivity Score (S10) | High (Off-target) | Moderate | Very High | | Resistance Profile | Low | Med (BTK-T474) | Low (Novel binding) |
RKI-609, also known as berberine hydrochloride, is a naturally occurring compound extracted from the Berberis plant. It has been used in traditional Chinese medicine for centuries to treat various health conditions, including metabolic disorders, digestive issues, and infections. In recent years, RKI-609 has gained significant attention for its potential therapeutic benefits in the management of chronic diseases, such as diabetes, obesity, and cardiovascular disease. This article provides an overview of RKI-609, its history, mechanism of action, and therapeutic applications.